Symbols / WVE $14.08 +2.40%
WVE Chart
About
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.65B |
| Enterprise Value | 2.07B | Income | -204.38M | Sales | 42.73M |
| Book/sh | 2.76 | Cash/sh | 3.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 317 | IPO | — |
| P/E | — | Forward P/E | -10.82 | PEG | — |
| P/S | 62.04 | P/B | 5.10 | P/C | — |
| EV/EBITDA | -9.79 | EV/Sales | 48.55 | Quick Ratio | 6.35 |
| Current Ratio | 6.47 | Debt/Eq | 3.38 | LT Debt/Eq | — |
| EPS (ttm) | -1.21 | EPS next Y | -1.30 | EPS Growth | — |
| Revenue Growth | -79.40% | Earnings | 2026-05-07 | ROA | -27.18% |
| ROE | -54.97% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -3.27% | Profit Margin | 0.00% | Shs Outstand | 188.25M |
| Shs Float | 129.88M | Short Float | 9.31% | Short Ratio | 4.32 |
| Short Interest | — | 52W High | 21.73 | 52W Low | 5.28 |
| Beta | -1.66 | Avg Volume | 3.42M | Volume | 1.76M |
| Target Price | $34.06 | Recom | Strong_buy | Prev Close | $13.75 |
| Price | $14.08 | Change | 2.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.06
Mean price target
2. Current target
$14.08
Latest analyst target
3. DCF / Fair value
$-10.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.08
Low
$22.00
High
$52.00
Mean
$34.06
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | main | Canaccord Genuity | Buy → Buy | $52 |
| 2026-03-06 | main | Wedbush | Outperform → Outperform | $35 |
| 2026-03-02 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2026-02-12 | main | Wells Fargo | Overweight → Overweight | $27 |
| 2026-02-05 | main | Cantor Fitzgerald | Overweight → Overweight | $41 |
| 2026-02-03 | main | Canaccord Genuity | Buy → Buy | $43 |
| 2025-12-19 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-12-16 | main | Oppenheimer | Outperform → Outperform | $32 |
| 2025-12-15 | main | Truist Securities | Buy → Buy | $50 |
| 2025-12-12 | main | B. Riley Securities | Buy → Buy | $37 |
| 2025-12-12 | main | Wedbush | Outperform → Outperform | $33 |
| 2025-12-09 | main | Citigroup | Buy → Buy | $30 |
| 2025-12-09 | main | Canaccord Genuity | Buy → Buy | $40 |
| 2025-12-09 | main | Wells Fargo | Overweight → Overweight | $29 |
| 2025-12-09 | main | Cantor Fitzgerald | Overweight → Overweight | $34 |
| 2025-12-09 | main | Clear Street | Buy → Buy | $47 |
| 2025-12-09 | up | RBC Capital | Sector Perform → Outperform | $27 |
| 2025-11-11 | main | Wedbush | Outperform → Outperform | $20 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $16 |
| 2025-10-15 | init | Clear Street | — → Buy | $22 |
News
RSS: Latest WVE news- Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat Fri, 06 Mar 2026 14
- Canaccord Genuity Boosts Price Target for WAVE Life Sciences (WV - GuruFocus Wed, 11 Mar 2026 03
- Experimental RNA treatment for alpha-1 gets late-breaking lung conference slot - Stock Titan hu, 05 Mar 2026 13
- WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally? - Yahoo Finance hu, 11 Dec 2025 08
- Wave Life Sciences: WVE-006 Now In Focus, Navigating Opportunity And Risk (NASDAQ:WVE) - Seeking Alpha ue, 17 Feb 2026 08
- Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed - simplywall.st Sun, 08 Mar 2026 09
- WAVE LIFE SCIENCES ($WVE) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 13
- WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga ue, 10 Mar 2026 18
- Wave Life Sciences Stock Jumps on Fresh Analyst Upgrade - TipRanks ue, 10 Mar 2026 15
- WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group - MarketBeat ue, 10 Mar 2026 17
- Wave obesity drug WVE-007 shows GLP-1-like fat loss in trial update - Stock Titan hu, 26 Feb 2026 08
- WVE: Wedbush Raises Price Target for WAVE Life Sciences, Reaffir - GuruFocus Fri, 06 Mar 2026 16
- Insider Sale: See Remarks of $WVE Sells 17,900 Shares - Quiver Quantitative Sat, 28 Feb 2026 08
- Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Yahoo Finance Sat, 28 Feb 2026 08
- Insider Purchase: 10% owner at $WVE Buys 1,470,000 Shares - Quiver Quantitative Mon, 15 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 33194 | 499593 | — | Sale at price 15.00 - 15.09 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-02-26 00:00:00 | D |
| 1 | 33194 | 141920 | — | Conversion of Exercise of derivative security at price 3.87 - 4.75 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-02-26 00:00:00 | D |
| 2 | 3588 | 48259 | — | Sale at price 13.45 per share. | MORAN KYLE | Chief Financial Officer | — | 2026-02-09 00:00:00 | D |
| 3 | 10480 | 140956 | — | Sale at price 13.45 per share. | BOLNO PAUL B. M.D. | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 4 | 3228 | 43417 | — | Sale at price 13.45 per share. | VARGEESE CHANDRA | Officer | — | 2026-02-09 00:00:00 | D |
| 5 | 1883 | 25326 | — | Sale at price 13.45 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-02-09 00:00:00 | D |
| 6 | 45625 | — | — | Stock Award(Grant) at price 0.00 per share. | MORAN KYLE | Chief Financial Officer | — | 2026-02-05 00:00:00 | D |
| 7 | 165000 | — | — | Stock Award(Grant) at price 0.00 per share. | BOLNO PAUL B. M.D. | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 8 | 45625 | — | — | Stock Award(Grant) at price 0.00 per share. | VARGEESE CHANDRA | Officer | — | 2026-02-05 00:00:00 | D |
| 9 | 38750 | — | — | Stock Award(Grant) at price 0.00 per share. | FRANCIS CHRISTOPHER JOHN | Officer | — | 2026-02-05 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 95.14K | 267.07K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.01 | 0.17 |
| NormalizedEBITDA | -217.01M | -111.90M | -66.72M | -154.18M |
| TotalUnusualItems | 10.48M | 10.16M | 7.93M | 1.57M |
| TotalUnusualItemsExcludingGoodwill | 10.48M | 10.16M | 7.93M | 1.57M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -204.38M | -97.01M | -57.51M | -161.82M |
| ReconciledDepreciation | 8.85M | 8.66M | 9.21M | 10.11M |
| EBITDA | -206.53M | -101.74M | -58.79M | -152.61M |
| EBIT | -215.38M | -110.40M | -68.00M | -162.72M |
| NormalizedIncome | -214.86M | -107.17M | -65.35M | -163.13M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -204.38M | -97.01M | -57.51M | -161.82M |
| TotalExpenses | 258.11M | 218.71M | 181.30M | 166.37M |
| TotalOperatingIncomeAsReported | -215.38M | -110.40M | -68.00M | -162.72M |
| DilutedAverageShares | 168.65M | 138.28M | 106.10M | 78.86M |
| BasicAverageShares | 168.65M | 138.28M | 106.10M | 78.86M |
| DilutedEPS | -1.21 | -0.70 | -0.54 | -2.05 |
| BasicEPS | -1.21 | -0.70 | -0.54 | -2.05 |
| DilutedNIAvailtoComStockholders | -204.38M | -97.01M | -57.51M | -161.82M |
| NetIncomeCommonStockholders | -204.38M | -97.01M | -57.51M | -161.82M |
| NetIncome | -204.38M | -97.01M | -57.51M | -161.82M |
| NetIncomeIncludingNoncontrollingInterests | -204.38M | -97.01M | -57.51M | -161.82M |
| NetIncomeContinuousOperations | -204.38M | -97.01M | -57.51M | -161.82M |
| TaxProvision | 0.00 | 0.00 | -677.00K | 681.00K |
| PretaxIncome | -204.38M | -97.01M | -58.19M | -161.14M |
| OtherIncomeExpense | 11.01M | 13.39M | 9.81M | 1.58M |
| OtherNonOperatingIncomeExpenses | 527.00K | 3.23M | 1.88M | 7.00K |
| GainOnSaleOfSecurity | 10.48M | 10.16M | 7.93M | 1.57M |
| OperatingIncome | -215.38M | -110.40M | -68.00M | -162.72M |
| OperatingExpense | 258.11M | 218.71M | 181.30M | 166.37M |
| ResearchAndDevelopment | 182.78M | 159.68M | 130.01M | 115.86M |
| SellingGeneralAndAdministration | 75.33M | 59.02M | 51.29M | 50.51M |
| GeneralAndAdministrativeExpense | 75.33M | 59.02M | 51.29M | 50.51M |
| OtherGandA | 75.33M | 59.02M | 51.29M | 50.51M |
| TotalRevenue | 42.73M | 108.30M | 113.31M | 3.65M |
| OperatingRevenue | 42.73M | 108.30M | 113.31M | 3.65M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 187.66M | 153.04M | 119.16M | 86.92M |
| ShareIssued | 187.66M | 153.04M | 119.16M | 86.92M |
| TotalDebt | 17.77M | 25.40M | 32.12M | 37.61M |
| TangibleBookValue | 518.36M | 209.51M | 39.63M | -45.09M |
| InvestedCapital | 518.36M | 209.51M | 39.63M | -45.09M |
| WorkingCapital | 519.75M | 209.44M | 48.93M | 27.02M |
| NetTangibleAssets | 518.36M | 209.51M | 39.63M | -45.09M |
| CapitalLeaseObligations | 17.77M | 25.40M | 32.12M | 37.61M |
| CommonStockEquity | 518.36M | 209.51M | 39.63M | -45.09M |
| TotalCapitalization | 518.36M | 209.51M | 39.63M | -45.09M |
| TotalEquityGrossMinorityInterest | 518.36M | 209.51M | 39.63M | -45.09M |
| StockholdersEquity | 518.36M | 209.51M | 39.63M | -45.09M |
| GainsLossesNotAffectingRetainedEarnings | -250.00K | -262.00K | -124.00K | -29.00K |
| OtherEquityAdjustments | -250.00K | -262.00K | -124.00K | -29.00K |
| RetainedEarnings | -1.33B | -1.12B | -1.02B | -967.34M |
| AdditionalPaidInCapital | 228.37M | 156.45M | 129.24M | 119.44M |
| CapitalStock | 1.62B | 1.18B | 935.37M | 802.83M |
| CommonStock | 1.62B | 1.18B | 935.37M | 802.83M |
| TotalLiabilitiesNetMinorityInterest | 120.14M | 142.69M | 235.32M | 191.48M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 25.08M | 31.74M | 48.88M | 119.96M |
| OtherNonCurrentLiabilities | 190.00K | |||
| PreferredSecuritiesOutsideStockEquity | 7.87M | 7.87M | 7.87M | 7.87M |
| NonCurrentDeferredLiabilities | 7.80M | 6.10M | 15.60M | 79.77M |
| NonCurrentDeferredRevenue | 7.80M | 6.10M | 15.60M | 79.77M |
| LongTermDebtAndCapitalLeaseObligation | 9.40M | 17.77M | 25.40M | 32.12M |
| LongTermCapitalLeaseObligation | 9.40M | 17.77M | 25.40M | 32.12M |
| CurrentLiabilities | 95.06M | 110.95M | 186.44M | 71.52M |
| CurrentDeferredLiabilities | 44.44M | 65.97M | 150.06M | 31.56M |
| CurrentDeferredRevenue | 44.44M | 65.97M | 150.06M | 31.56M |
| CurrentDebtAndCapitalLeaseObligation | 8.36M | 7.64M | 6.71M | 5.50M |
| CurrentCapitalLeaseObligation | 8.36M | 7.64M | 6.71M | 5.50M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 18.08M | 15.36M | 14.06M | 12.29M |
| PayablesAndAccruedExpenses | 24.18M | 21.98M | 15.60M | 22.18M |
| CurrentAccruedExpenses | 8.48M | 5.72M | 2.76M | 5.26M |
| Payables | 15.70M | 16.26M | 12.84M | 16.91M |
| AccountsPayable | 15.70M | 16.26M | 12.84M | 16.91M |
| TotalAssets | 638.50M | 352.21M | 274.95M | 146.39M |
| TotalNonCurrentAssets | 23.68M | 31.81M | 39.58M | 47.85M |
| OtherNonCurrentAssets | 3.82M | 3.81M | 3.85M | 3.72M |
| NetPPE | 19.86M | 28.00M | 35.72M | 44.13M |
| AccumulatedDepreciation | -49.52M | -46.33M | -42.71M | -37.85M |
| GrossPPE | 69.39M | 74.33M | 78.43M | 81.97M |
| Leases | 28.94M | 28.89M | 28.52M | 28.41M |
| ConstructionInProgress | 598.00K | 349.00K | 294.00K | 318.00K |
| OtherProperties | 12.46M | 17.87M | 22.64M | 26.84M |
| MachineryFurnitureEquipment | 27.39M | 27.22M | 26.97M | 26.40M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 614.81M | 320.39M | 235.37M | 98.54M |
| OtherCurrentAssets | 3.08M | 7.35M | 4.02M | 2.11M |
| PrepaidAssets | 8.39M | 9.54M | 9.91M | 7.93M |
| Receivables | 1.28M | 1.42M | 21.09M | 0.00 |
| AccountsReceivable | 1.28M | 1.42M | 21.09M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 602.07M | 302.08M | 200.35M | 88.50M |
| CashAndCashEquivalents | 602.07M | 302.08M | 200.35M | 88.50M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -188.21M | -151.96M | -20.55M | -129.14M |
| IssuanceOfCapitalStock | 472.49M | 236.18M | 131.28M | 52.33M |
| CapitalExpenditure | -718.00K | -938.00K | -1.11M | -1.36M |
| EndCashPosition | 605.87M | 305.84M | 204.05M | 92.16M |
| BeginningCashPosition | 305.84M | 204.05M | 92.16M | 154.22M |
| EffectOfExchangeRateChanges | 12.00K | -138.00K | -95.00K | -210.00K |
| ChangesInCash | 300.02M | 101.93M | 111.99M | -61.85M |
| FinancingCashFlow | 488.24M | 253.89M | 132.53M | 67.19M |
| CashFlowFromContinuingFinancingActivities | 488.24M | 253.89M | 132.53M | 67.19M |
| ProceedsFromStockOptionExercised | 15.75M | 17.71M | 1.26M | 14.86M |
| NetCommonStockIssuance | 472.49M | 236.18M | 131.28M | 52.33M |
| CommonStockIssuance | 472.49M | 236.18M | 131.28M | 52.33M |
| InvestingCashFlow | -718.00K | -938.00K | -1.11M | -1.25M |
| CashFlowFromContinuingInvestingActivities | -718.00K | -938.00K | -1.11M | -1.25M |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 0.00 | 0.00 |
| SaleOfInvestment | 0.00 | 0.00 | 75.04M | 0.00 |
| PurchaseOfInvestment | 0.00 | 0.00 | -75.04M | 0.00 |
| NetPPEPurchaseAndSale | -718.00K | -938.00K | -1.11M | -1.25M |
| SaleOfPPE | 0.00 | 0.00 | 106.00K | 0.00 |
| PurchaseOfPPE | -718.00K | -938.00K | -1.11M | -1.36M |
| OperatingCashFlow | -187.49M | -151.03M | -19.43M | -127.78M |
| CashFlowFromContinuingOperatingActivities | -187.49M | -151.03M | -19.43M | -127.78M |
| ChangeInWorkingCapital | -16.94M | -75.82M | 19.08M | 6.72M |
| ChangeInOtherWorkingCapital | -19.83M | -93.59M | 54.33M | -3.25M |
| ChangeInOtherCurrentLiabilities | -7.64M | -6.71M | -5.69M | -4.12M |
| ChangeInOtherCurrentAssets | 4.31M | -3.23M | -2.01M | 3.39M |
| ChangeInPayablesAndAccruedExpense | 4.92M | 7.67M | -4.49M | 12.04M |
| ChangeInAccruedExpense | 5.48M | 4.25M | -724.00K | 2.69M |
| ChangeInPayable | -561.00K | 3.42M | -3.76M | 9.35M |
| ChangeInAccountPayable | -561.00K | 3.42M | -3.76M | 9.35M |
| ChangeInPrepaidAssets | 1.15M | 368.00K | -1.98M | -1.35M |
| ChangeInReceivables | 146.00K | 19.66M | -21.09M | 0.00 |
| ChangesInAccountReceivables | 146.00K | 19.66M | -21.09M | 0.00 |
| StockBasedCompensation | 24.97M | 13.14M | 9.79M | 17.19M |
| DepreciationAmortizationDepletion | 8.85M | 8.66M | 9.21M | 10.11M |
| DepreciationAndAmortization | 8.85M | 8.66M | 9.21M | 10.11M |
| Depreciation | 8.85M | 8.66M | 9.21M | 10.11M |
| OperatingGainsLosses | 12.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 12.00K | 0.00 |
| NetIncomeFromContinuingOperations | -204.38M | -97.01M | -57.51M | -161.82M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for WVE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|